Concordia Announces Second Quarter 2017 Results
OAKVILLE, ON, Aug. 11, 2017 /PRNewswire/ - Concordia International Corp. ("Concordia" or the "Company") (NASDAQ: CXRX) (TSX: CXR), an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced its financial and operational results for the three and six months ended June 30, 2017. All financial references are in U.S. dollars (USD) unless otherwise noted.
"Our second quarter results were in line with our expectations, which can be attributed to our business stabilization initiatives taken to date," said Allan Oberman, Chief Executive Officer of Concordia. "During the quarter, we also finalized our long-term growth strategy, with the full support of our Board of Directors. Our new long-term growth strategy, known going forward as the DELIVER strategy, seeks to accelerate growth by maximizing our existing assets and future market opportunities, expanding our product portfolio, optimizing our operating platform and strengthening our financial foundation. We look forward to sharing the detailed initiatives that comprise the DELIVER strategy by mid September."
"Our second quarter results were in line with our expectations, which can be attributed to our business stabilization initiatives taken to date," said Allan Oberman, Chief Executive Officer of Concordia. "During the quarter, we also finalized our long-term growth strategy, with the full support of our Board of Directors. Our new long-term growth strategy, known going forward as the DELIVER strategy, seeks to accelerate growth by maximizing our existing assets and future market opportunities, expanding our product portfolio, optimizing our operating platform and strengthening our financial foundation. We look forward to sharing the detailed initiatives that comprise the DELIVER strategy by mid September."